-
Healthcare
First FDA-approved MS therapeutic: Tyruko® (natalizumab-sztn)
A biosimilar developed by Polpharma Biologics, Tyruko®, was unveiled as the first and only FDA-approved for the treatment of Multiple Sclerosis (MS) on 25 August 2023. The drug has not only been prescribed for the relapsing forms of multiple sclerosis, but also a potential therapeutic for Crohn’s disease (CD). Multiple…
Read More »